Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity.’ The study aimed to assess whether CagriSema can reduce kidney damage in individuals with chronic kidney disease, type 2 diabetes, and obesity, compared to semaglutide, cagrilintide, and placebo. This research is significant as it explores potential new treatments for a vulnerable patient group.
Intervention/Treatment: The study tested the combination of two drugs, Cagrilintide and Semaglutide, known as CagriSema. These drugs are administered subcutaneously and are intended to reduce kidney damage in the target population.
Study Design: This Phase 2 interventional study was randomized and used a parallel assignment model. It employed quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors were unaware of the treatment allocations. The primary purpose of the study was treatment-focused.
Study Timeline: The study was first submitted on November 9, 2023, and the last update was submitted on November 26, 2025. These dates mark the progression and updates of the study, indicating its completion and the availability of new data.
Market Implications: The completion of this study could positively impact Novo Nordisk’s stock performance and investor sentiment, as it highlights potential advancements in treating chronic kidney disease and type 2 diabetes. Competitors in the pharmaceutical industry will likely monitor these developments closely, as successful outcomes could shift market dynamics.
The study is now completed, and further details are available on the ClinicalTrials portal.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.